These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9483173)

  • 1. In vitro analysis of synergistic effects of fibrinolytic agents and prostacyclin analogues.
    Spiecker M; Heinke B; Meyer J; Darius H
    Haemostasis; 1997; 27(4):184-92. PubMed ID: 9483173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Taprostene, a stable prostacyclin analogue, enhances the thrombolytic efficacy of saruplase (recombinant single-chain urokinase-type plasminogen activator) in rabbits with pulmonary embolized thrombi.
    Schneider J
    Prostaglandins; 1991 Jun; 41(6):595-606. PubMed ID: 2052741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of thrombolytic, fibrinolytic, and fibrinogenolytic properties of tissue plasminogen activator, streptokinase, single-chain urokinase, high molecular weight and low molecular weight urokinase in human plasma in vitro.
    Samama M; Nguyen G; Desnoyers P; Lourenco DM; Fretault J; Horellou MH; Conard J; Szwarcer E; Verdy E; Vahanian A
    Fundam Clin Pharmacol; 1988; 2(6):509-23. PubMed ID: 3149257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pro-urokinase for infarct therapy].
    Spiecker M; Meyer J
    Herz; 1994 Dec; 19(6):326-35. PubMed ID: 7843689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impairment of fibrinolysis by streptokinase, urokinase and recombinant tissue-type plasminogen activator in the presence of radiographic contrast agents.
    Dehmer GJ; Gresalfi N; Daly D; Oberhardt B; Tate DA
    J Am Coll Cardiol; 1995 Apr; 25(5):1069-75. PubMed ID: 7897118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The search for the ideal thrombolytic agent.
    Verstraete M
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):4B-10B. PubMed ID: 2959714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ancrod enhances the thrombolytic effect of streptokinase and urokinase.
    Cercek B; Lew AS; Hod H; Yano J; Lewis B; Reddy KN; Ganz W
    Thromb Res; 1987 Aug; 47(4):417-26. PubMed ID: 3660351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology of platelet-inhibitory drugs, anticoagulants, and thrombolytic agents.
    Mehta JL; Kitchens CS
    Cardiovasc Clin; 1987; 18(1):163-79. PubMed ID: 3111692
    [No Abstract]   [Full Text] [Related]  

  • 9. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
    Gurewich V; Pannell R
    Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
    [No Abstract]   [Full Text] [Related]  

  • 10. Thrombin inhibitory and clot-specific fibrinolytic activities of the urokinase variant, M23 (rscu-PA-40 kDa/Hir).
    Schneider J; Wnendt S; Saunders D; Heinzel-Wieland R; Wilffert B; Steffens G
    Eur J Pharmacol; 1996 Apr; 302(1-3):69-77. PubMed ID: 8790994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of saruplase, a recombinant unglycosylated human single-chain urokinase-type plasminogen activator and its effects on fibrinolytic and haemostatic parameters in healthy male subjects.
    de Boer A; Kluft C; Gerloff J; Dooijewaard G; Günzler WA; Beier H; van der Meer FJ; Cohen AF
    Thromb Haemost; 1993 Aug; 70(2):320-5. PubMed ID: 8236142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of fibrinolytic properties of Alteplase, Tenecteplase and Urokinase in an in vitro clot model of intracerebral haemorrhage.
    Keric N; Döbel M; Krenzlin H; Kurz E; Tanyildizi Y; Heimann A; König J; Kempski O; Ringel F; Masomi-Bornwasser J
    J Stroke Cerebrovasc Dis; 2020 Sep; 29(9):105073. PubMed ID: 32807475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of fibrinolysis.
    Haire WD
    Chest; 1992 Apr; 101(4 Suppl):91S-97S. PubMed ID: 1555484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saruplase versus other fibrinolytic agents.
    Michels HR
    Int J Clin Pract Suppl; 1998 Nov; 99():21-2. PubMed ID: 10344037
    [No Abstract]   [Full Text] [Related]  

  • 16. [New thrombolytic agents].
    Nguyen G; Samama M
    Ann Biol Clin (Paris); 1987; 45(2):212-8. PubMed ID: 3113300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of superoxide production in human neutrophils by combinations of heparin and thrombolytic agents.
    Riesenberg K; Schlaeffer F; Katz A; Levy R
    Br Heart J; 1995 Jan; 73(1):14-9. PubMed ID: 7888254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
    Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactivity of D-dimer assays with the fibrinogen--fibrin split products generated by thrombolytic agents.
    Amiral J; Minard F; Plassart V; Vissac AM; Chambrette B
    Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):525-30. PubMed ID: 2133230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of taprostene in patients with acute myocardial infarction treated with thrombolytic therapy: results of the START study. Saruplase Taprostene Acute Reocclusion Trial.
    Bär FW; Meyer J; Michels R; Uebis R; Lange S; Barth H; Groves R; Vermeer F
    Eur Heart J; 1993 Aug; 14(8):1118-26. PubMed ID: 8404943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.